We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Moderna (MRNA - Free Report) closed the most recent trading day at $142.52, moving +0.06% from the previous trading session. This change lagged the S&P 500's 2.48% gain on the day. Meanwhile, the Dow gained 1.85%, and the Nasdaq, a tech-heavy index, lost 0.18%.
Coming into today, shares of the biotechnology company had lost 18.57% in the past month. In that same time, the Medical sector lost 4.76%, while the S&P 500 lost 7.81%.
Moderna will be looking to display strength as it nears its next earnings release, which is expected to be May 4, 2022. On that day, Moderna is projected to report earnings of $5.18 per share, which would represent year-over-year growth of 82.39%. Our most recent consensus estimate is calling for quarterly revenue of $4.5 billion, up 132.48% from the year-ago period.
MRNA's full-year Zacks Consensus Estimates are calling for earnings of $26.95 per share and revenue of $22.14 billion. These results would represent year-over-year changes of -4.74% and +19.85%, respectively.
Any recent changes to analyst estimates for Moderna should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.46% higher. Moderna is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Moderna is holding a Forward P/E ratio of 5.28. Its industry sports an average Forward P/E of 20.78, so we one might conclude that Moderna is trading at a discount comparatively.
Investors should also note that MRNA has a PEG ratio of 0.81 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. MRNA's industry had an average PEG ratio of 1.34 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 143, putting it in the bottom 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Gains But Lags Market: What You Should Know
Moderna (MRNA - Free Report) closed the most recent trading day at $142.52, moving +0.06% from the previous trading session. This change lagged the S&P 500's 2.48% gain on the day. Meanwhile, the Dow gained 1.85%, and the Nasdaq, a tech-heavy index, lost 0.18%.
Coming into today, shares of the biotechnology company had lost 18.57% in the past month. In that same time, the Medical sector lost 4.76%, while the S&P 500 lost 7.81%.
Moderna will be looking to display strength as it nears its next earnings release, which is expected to be May 4, 2022. On that day, Moderna is projected to report earnings of $5.18 per share, which would represent year-over-year growth of 82.39%. Our most recent consensus estimate is calling for quarterly revenue of $4.5 billion, up 132.48% from the year-ago period.
MRNA's full-year Zacks Consensus Estimates are calling for earnings of $26.95 per share and revenue of $22.14 billion. These results would represent year-over-year changes of -4.74% and +19.85%, respectively.
Any recent changes to analyst estimates for Moderna should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.46% higher. Moderna is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Moderna is holding a Forward P/E ratio of 5.28. Its industry sports an average Forward P/E of 20.78, so we one might conclude that Moderna is trading at a discount comparatively.
Investors should also note that MRNA has a PEG ratio of 0.81 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. MRNA's industry had an average PEG ratio of 1.34 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 143, putting it in the bottom 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.